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Summary
 
Limited information is available on the surface molecules that are involved in natural killer (NK)
cell triggering. In this study, we selected the BAB281 monoclonal antibody (mAb) on the basis
of its ability to trigger NK-mediated target cell lysis. BAB281 identified a novel NK cell–spe-
cific surface molecule of 46 kD (p46) that is expressed by all resting or activated NK cells. Im-
portantly, unlike the NK cell antigens identified so far, the expression of p46 was strictly con-
fined to NK cells. Upon mAb-mediated cross-linking, p46 molecules induced strong cell
triggering leading to [Ca
 
2
 
1
 
]i increases, lymphokine production, and cytolytic activity both in
resting NK cells and NK cell clones. The p46-mediated induction of Ca
 
2
 
1
 
 increases or trigger-
ing of cytolytic activity was downregulated by the simultaneous engagement of inhibitory re-
ceptors including p58, p70, and CD94/NKG2A. Both the unique cellular distribution and
functional capability of p46 molecules suggest a possible role in the mechanisms of non-major
histocompatibility complex–restricted cytolysis mediated by human NK cells.
 
N
 
atural killer (NK) cells were originally described on a
functional basis in accordance to their ability to lyse
certain tumor cells in the absence of previous stimulation
(1, 2). The molecular mechanism that explains why NK cells
do not kill indiscriminately but spare normal cells has recently
been clarified (3). NK cells express several receptors that rec-
ognize MHC class I molecules expressed on normal cells (4,
5). The lack of expression of one or more MHC class I alleles
leads to NK-mediated target cell lysis. In humans, different
receptors specific for groups of HLA-C, HLA-B, or HLA-A
alleles have been identified (6). They belong to the Ig super-
family and are characterized by two or three extracellular Ig-
like domains (7–9). A second type of HLA-specific receptors
is formed by the association of CD94 molecules with mem-
bers of the NKG2 family (10–13). While detailed informa-
tion is now available on the receptors and the molecular
mechanisms leading to NK cell inactivation, the cell surface
molecules responsible for NK cell activation have only par-
tially been identified. While both the ligand and the signaling
events mediated by CD16 have been defined and analyzed
in detail (14, 15), little is known on the receptors and ligands
involved in lysis of NK-susceptible target cells. It is likely
that different receptor–ligand interactions may be responsi-
ble for NK cell activation upon interaction with target cells.
However, evidence for a direct involvement of a surface mol-
ecule in natural cytotoxicity has been achieved only for mu-
rine (but not human) NKR-P1 against certain target cells
(16). In this context, the identification of novel triggering
molecules in human NK cells may lead to a better definition
of the surface structures involved in the induction of NK
cell–mediated cytotoxicity.
In this study we identified a novel surface molecule (p46)
that induces strong NK cell triggering and, unlike from all of
the other NK cell antigens, is expressed exclusively by NK cells.
 
Materials and Methods
 
Antibodies.
 
mAb JT3A (IgG
 
2
 
a anti-CD3), GL183 (IgG
 
1
 
 anti-
p58.2), Y249 (IgM anti-p58.2), EB6 (IgG
 
1
 
 anti-p58.1), XA-141
(IgM anti-p58.1), PAX250 (IgG
 
1
 
 anti-p50.3), FES 172 (IgG
 
2
 
a
anti-p50.3), Z27 (IgG
 
1
 
 anti-p70), XA-185 (IgG
 
1
 
 anti-CD94), Y9
(IgM anti-CD94), Z199 and Z270 (IgG
 
2
 
b and IgG
 
1
 
, respectively,
anti-NKG2A), KD1 (IgG
 
2
 
a anti-CD16), c127 (IgG
 
1
 
 anti-CD16),
c218 (IgG
 
1
 
 anti-CD56), and A6-220 (IgM anti-CD56) were pro-
duced in our lab. D1.12 (IgG
 
2
 
a anti-HLA-DR), HP2.6 (IgG
 
2
 
a
anti-CD4), and B9.4 (IgG
 
2
 
b anti-CD8) mAbs were provided by
Drs. R.S. Accolla (Università di Pavia, Pavia, Italy), P. Sanchez-
Madrid (Hospital de la Princesa, Madrid, Spain), and B. Malissen
(Centre de Immunologie INSERM/CNRS, Marseille, France).
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Production of mAb and Flow Cytofluorometric Analysis.
 
BAB281
mAb (IgG
 
1
 
) was obtained by immunizing a 5-wk-old Balb/C
mouse with the NK cell clone SE192. Analysis of the cell distri-
bution of p46 molecules was performed by using a FACScan
 
Ò
 
one- or two-color fluorescence cytofluorometric analysis as pre-
viously described (17).
 
Cytolytic Activity and Lymphokine Production by NK Cell Clones.
 
T or NK cell clones were obtained by limiting dilution, as previ-
ously described (18). The cytolytic activity was assessed in a 4 h
 
51
 
Cr-release assay (18) in which effector cells were tested against
the K562 or the P815 cell lines. The quantitative determination
of TNF-
 
a
 
 and IFN-
 
g
 
 production (19) by NK cell clones was
performed by an enzyme immunoassay purchased from Genzyme
Corp. (Cambridge, MA). The sensitivity of the two tests ranged
from 15 to 1,200 and from 16 to 1,024 pg/ml, respectively.
 
Determination of Intracellular Free Calcium [Ca
 
2
 
1
 
]i Increases.
 
Determination of [Ca
 
2
 
1
 
]i was performed as previously described
(19). Triggering of NK cells was achieved by adding into the cu-
vette 5 
 
m
 
g/ml of mAb followed by the addition of 20 
 
m
 
g/ml
polyclonal isotype–specific goat anti–mouse (Southern Biotech-
nology Associated, Birmingham, AL).
 
Biochemical Characterization of the p46 Molecules.
 
Cyanogen bro-
mide sepharose (Pharmacia Biotech Inc., Piscataway, NJ)–cou-
pled BAB281 or Sepharose PA–coupled KD1 mAbs were used to
immunoprecipitate specific molecules from 1% NP-40 lysates of
cells surface-labeled with 
 
125
 
I (DuPont–New England Nuclear,
Boston, MA) as previously described (17). Immunoprecipitates
were analyzed by discontinuous SDS-PAGE.
Specific bands were cut out from dried gel and eluted proteins
were used for 
 
N
 
-glycanase, neuraminidase, or neuraminidase fol-
lowed by 
 
O
 
-glycanase (Genzyme Corp.) digestion (19). For one-
dimensional peptide mapping (19), cut bands were loaded on a
15–20% gradient gel and digestion was performed by adding 500
ng of endoproteinase Glu-C (V8 protease) or papain (Sigma
Chemical Co., St. Louis, MO) to each well.
 
Purification of NK Cell–enriched or NK Cell–depleted Peripheral
Blood Populations.
 
To obtain an NK cell–enriched lymphocyte
population, PBMCs were depleted of plastic-adherent cells and
subsequently incubated with anti-CD3 (JT3A) mAb for 30 min at
4
 
8
 
C followed by treatment with goat anti–mouse–coated Dyna-
beads (Dynal, Oslo, Norway) for 30 min at 4
 
8
 
C. The resulting
CD3
 
2
 
 lymphocyte populations contained 
 
z
 
1% CD3
 
1
 
 cells, 20%
HLA-DR
 
1
 
 cells, and 80% CD56
 
1
 
 cells. These cells were used for
FACS
 
Ò
 
 analysis of CD3-depleted populations (see Fig. 3) and for
cytolytic activity against K562 and P815 target cells (see Fig. 6 
 
a
 
).
In another set of experiments, PBMCs were stained for both anti-
CD3 and anti-p46 mAb and subsequently cells lacking the expres-
sion of p46 or CD3 or both markers (CD3
 
2
 
, p46
 
2
 
) were sorted and
analyzed for cytolytic activity against K562 target cells (see Fig. 6 
 
b
 
).
 
Results
 
Selection of mAb Identifying a 46-kD Surface Molecule In-
volved in Triggering of NK Cell–mediated Cytolytic Activity.
 
Mice were immunized with the CD3
 
2
 
,16
 
1
 
,56
 
1
 
 NK cell
clone SE192 which did not express p58, p70, or p140 NK
cell receptor, while it expressed the CD94/NKG2A inhibi-
tory receptor complex identified by the Z199 and Z270
mAbs (11, 12). mAbs were selected on the basis of the abil-
ity to modulate the cytolytic activity of the immunizing
clone in a redirected killing assay against murine P815 tar-
get cells. The selected mAb (BAB281) induced a sharp in-
crease of the cytolytic activity of clone SE192 (Fig. 1 
 
a
 
) as
well as that of a panel of NK cell clones expressing one or
more NKR. The magnitude of NK cell triggering induced
by BAB281 mAb was comparable to that induced by anti-
CD16 mAb under the same experimental conditions (Fig.
1 
 
a
 
). On the other hand, a negative control represented by
the c218 (isotype-matched, IgG
 
1
 
, anti-CD56) mAb that
binds to the NK cell clone, ruled out a nonspecific effect of
BAB281 mAb. Surface molecules recognized by BAB281
mAb were analyzed by SDS-PAGE after immunoprecipita-
tion from cell lysates derived from 
 
125
 
I-labeled NK cell
populations or clones. As shown in Fig. 1 
 
b
 
, BAB281 mAb
Figure 1. Triggering of cytolytic activity and molecular characteristics
of the novel 46-kD NK cell surface molecule. (a) The NK clone SE192,
used for mice immunization, was analyzed in a redirected killing assay
against P815 target cells in the presence of graded amounts of BAB281
(m), c127 (anti-CD16) (s), or c218 (anti-CD56) (j) mAbs. All these
mAbs are IgG1. (b) NK cell populations derived from donor E.C. (lanes A
and D) or donor L.M. (lanes B and E) and the NK cell clone 211 derived
from donor F.G. (lanes C and F) were surface labeled with 125I and im-
munoprecipitated with BAB281 mAb. Samples were analyzed in a 8%
SDS-PAGE under nonreducing (lanes A–C) or reducing (lanes D–F)
conditions. All the mAbs used here were of the IgG1 isotype. 
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immunoprecipitated a single protein of 
 
z
 
46 kD under both
reducing and nonreducing conditions (hereafter termed
p46). The comparative analysis of the effect of deglycosyla-
tion of p46 or CD16 molecules revealed important differ-
ences. As shown in Fig. 2 
 
a
 
, the mobility of p46 molecules
was not modified by treatment with 
 
N
 
-glycanase, whereas
only a slight decrement in molecular weight was induced
by neuraminidase followed by 
 
O
 
-glycanase treatment. This
suggests that, unlike from CD16 (20), p46 molecules do not
contain N-linked sugars (whereas 
 
O
 
-linked sugars may be
present). Further comparative analysis of p46 and CD16
molecules in one-dimensional peptide mapping revealed
that the pattern of digestion of the two molecules with ei-
ther V8 protease or papain was clearly different (Fig. 2 
 
b
 
).
Although not shown, the molecular characteristics of p46
molecules were also clearly distinct from other surface mol-
ecules mediating NK cell activation, including CD69 and
p50. In particular, because of the similar molecular size,
p50 and p46 were further compared. First, anti-p46 mAb
did not react with cell transfectants expressing one or an-
other member of the p50 family (19, 21); second, p46 mol-
ecules did not contain N-linked sugars (Fig. 2 
 
a
 
) whereas
p50 molecules did (19, 21). Finally, preclearing experi-
ments on an NK cell clone displaying the p50.3
 
1
 
,p46
 
1
 
phenotype indicated that after removal of p46 molecules
p50.3 molecules could still be immunoprecipitated and vice
versa (not shown). Therefore, it appears that BAB281 mAb
identifies a novel surface molecule involved in triggering of
NK cell–mediated cytotoxicity.
 
Cell Surface Distribution of p46 Molecules.
 
Analysis of the
cell distribution of p46 molecules was performed by indirect
immunofluorescence and FACS
 
Ò
 
 analysis on cultured NK
or T cell-enriched populations or clones. All the polyclonal
NK cell populations analyzed (
 
.
 
30) were homogeneously
stained by BAB281 mAb. In addition, all the NK cell clones
analyzed (
 
.
 
100), including infrequent clones characterized by
the CD3
 
2
 
56
 
1
 
16
 
2
 
 surface phenotype (22), were stained by
BAB281 mAb (not shown). On the other hand, P46 was
not expressed in T cell lines, PHA-induced polyclonal T
cell populations, or T cell clones (
 
.
 
200 analyzed including
both TCR-
 
a
 
/
 
b
 
1
 
 and -
 
g
 
/
 
d
 
1
 
 clones). Moreover, anti-p46
mAb did not stain B lymphocytes, EBV-induced B cell
lines, or nonhematopoietic cell lines (not shown).
We also analyzed the reactivity of BAB281 mAb on
freshly isolated PBMCs. A representative experiment is
shown in Fig. 3. It can be seen that p46 molecules were
undetectable in CD3
 
1
 
 lymphocytes (Fig. 3 
 
a
 
) and were
uniquely expressed in CD56
 
1
 
 cells (Fig. 3 
 
b). A small frac-
tion of CD561 cells was not stained by BAB281 mAb (Fig.
3 b); this subset (which is not detectable in all donors) is
represented by CD31 cells co-expressing CD56 (Fig. 3 c).
Indeed, experiments performed in PBLs (i.e., after removal
of adherent cells) depleted of CD31 cells (Fig. 3, e–g)
showed that all CD32CD561 cells co-expressed p46 mole-
cules (Fig. 3 f). In addition, it is evident that p46 molecules
are also expressed by the CD56brightCD162 NK cell subset
(reference 22; Fig. 3, e and g). Thus p46, in addition to me-
diating NK cell triggering, represents a marker that pre-
cisely defines all mature NK cells. In this context, it should
be stressed that CD16 is not expressed by all NK cells and
that both CD16 and CD56 are expressed also by rare T
cells (2).
P46 Molecules Induce Both Cytolytic Activity and Cytokine
Production in NK Cells. A panel of .100 NK cell clones
were assessed for cytolytic activity in the presence of BAB281
or anti-CD16 (c127) mAbs in a redirected killing assay
against the FcgR1 P815 target cells. Some of these clones
were also analyzed for lymphokine production in the pres-
ence of plastic adherent BAB281 mAb. The cytolytic activ-
ity of 10 representative NK cell clones is shown in Fig. 4 a.
It can be seen that most NK cell clones displayed strong cy-
tolytic responses to both anti-p46 and anti-CD16 mAbs,
whereas no increments of cytolytic activity were observed
in the presence of the isotype-matched (anti-CD56, IgG1)
c218 mAb. Anti-p46 mAb also triggered two clones (B1
and B2), which did not respond to anti-CD16 mAb. These
two clones are representative of the rare peripheral blood
NK cells displaying the CD32561162 phenotype. Some
differences in the staining intensity with anti-p46 mAb was
observed among different NK cell clones (not shown). In-
Figure 2. Deglycosylation and
proteolytic digestion of p46 mole-
cules. (a) CD16 (lanes A–D) or p46
(lanes E–H) molecules isolated from
a surface labeled NK cell population
were treated with neuraminidase
(lanes  B and F), neuraminidase plus
O-glycanase (lanes C and G), or
N-glycanase (lanes D and H). Un-
treated molecules are shown in lanes
A and E. Samples were run in an
11% SDS-PAGE under reducing
conditions. (b) p46 and CD16 mole-
cules immunoprecipitated from a
surface labeled NK cell population
were analyzed by SDS-PAGE. Bands
corresponding to p46 (lanes A, C, E,
and G) or CD16 (lanes B, D, F, and H) molecules were excised from the gel and analyzed by SDS-PAGE on a 15–20% gradient gel under reducing con-
ditions after digestion with V8 protease (lanes C and D) or papain (lanes G and H). In lanes A, B, E, and F untreated molecules are shown.1132 A Novel Receptor Involved in Natural Killer Cell Triggering
terestingly, this appears to correlate, at least partly, with the
degree of anti-p46–induced cytolytic activity as well as
with the spontaneous cytolytic activity of the different NK
cell clones. Although not shown, the p46-mediated NK
cell triggering was not induced by the (Fab9)2 fragment of
anti-p46 mAb. These data indicate that cross-linking of p46
molecules is required in order to induce triggering of NK
cell-mediated cytolytic activity. Indeed, lysis of FcgR2 tar-
get cells was not incremented by anti-p46 mAbs. On the
other hand, a partial inhibition mediated by anti-p46 mAb
could be detected against some FcgR2 target cells (includ-
ing C1R and IGROV cell lines). At present it is not clear
whether this inhibition reflects the interference with the
interaction between p46 and its putative ligand expressed
by these target cells.
Experiments of lymphokine production showed that
plastic-adherent BAB281 mAb induced strong production
of both IFN-g and TNF-a in all the NK cell clones ana-
lyzed (Fig. 4, b and c).
As expected, cytolytic T cell clones expressing either
TCR-a/b or -g/d were not responsive to anti-p46 mAb
(they were p462), whereas they were efficiently triggered
by anti-CD3 mAb. Remarkably, among the T cell clones
analyzed, some displayed NK cell-like activity and ex-
pressed HLA class I–specific NK cell receptors. In spite of
their phenotypic and functional features they did not ex-
press p46 molecules.
Figure 3. Analysis of the ex-
pression of p46 molecules in pe-
ripheral blood NK cells. In these
experiments freshly isolated PB-
MCs either unfractionated (a–d)
or depleted of both adherent cells
and CD31 lymphocytes (e–g)
were analyzed by two-color im-
munofluorescence and FACSÒ
analysis for the expression of p46
surface molecules in combina-
tion with the indicated surface
markers. Cells were stained with
mAbs to the indicated molecules
followed by FITC or PE-conju-
gated isotype-specific goat anti–
mouse second reagent. The contour plots were divided into quadrants
representing unstained cells (lower left), cells with only red fluorescence
(upper left), cells with red and green fluorescence (upper right), and cells
with only green fluorescence (lower right).
Figure 4. All human NK cell clones can be triggered via p46 molecule.
(a) 10 NK cell clones (representative of .100 clones analyzed) were as-
sessed for cytolytic activity against the FcgR1 P815 target cells in the ab-
sence (h) or presence of anti-p46 mAb (j), anti-CD16 mAb ( ), or
anti-CD56 mAb ( ). Two clones (B1 and B2) representative of the in-
frequent CD561162 NK cell clones, were triggered only by anti-p46
mAb. (b and c) Three representative NK cell clones were analyzed for
IFN-g or TNF-a production in the absence (h) or presence of anti-p46
mAb (j) or anti-CD56 mAb ( ).1133 Sivori et al.
Cross-linking of Inhibitory NKR Downregulates NK Cell
Triggering via p46. As shown above, BAB281 mAb trig-
gered all the NK cell clones (including those expressing
p58 or p70 NKR). Cross-linking of p58 (23) or p70 (24,
25) NKR results in inhibition of the CD16-mediated NK
cell triggering. We therefore analyzed whether NK cell
triggering via p46 could also be downregulated by cross-
linking of the inhibitory NKRs. To this end, a series of NK
cell clones expressing inhibitory NKRs were analyzed for
their cytolytic activity in the presence of both anti-p46 and
anti-NKR mAbs (Fig. 5). For example, clone KK26 ex-
pressed the p58.1 (EB6) receptors; it is evident that trigger-
ing of target cell lysis induced by BAB281 mAb was
strongly inhibited in the presence of anti-p58.1 mAbs (but
not by an isotype-matched anti-CD56 mAb). A similar ef-
fect was exerted by mAb-mediated cross-linking of other
inhibitory receptors (see the p701 clone LO1 and the
CD94/NKG2A1 clone KK4).
Triggering of Cytolytic Activity in Freshly Isolated NK Cells.
Since p46 molecules were also expressed by peripheral
blood NK cells, we analyzed whether anti-p46 mAb could
trigger the cytolytic activity of fresh NK cells as well. To
this end, NK cell–enriched populations were obtained
from peripheral blood populations after adherence by re-
moving CD31 cells. These populations were analyzed for
their ability to lyse K562 or P815 target cells (both FcgR1)
either in the presence or in the absence of BAB281 mAb.
As shown in Fig. 6, BAB281 mAb induced a strong in-
crease of cytolytic activity against both target cells. A simi-
lar effect was detected with anti-CD16 mAbs but not with
isotype-matched anti-CD56 mAb. To show that p46 mol-
ecules are expressed on all freshly isolated lymphocytes dis-
playing NK cell activity, we analyzed various lymphocyte
subsets for the ability to kill K562 target cells. To avoid re-
directed killing due to coating with mAb during the sorting
procedures, we analyzed only NK cells negatively selected
for the expression of the various markers. As shown in Fig.
6 b, PBL depleted of p461 or p461 and CD31 cells (p462
or p462/CD32) lost the ability to kill K562 target cells. On
the other hand, CD32 cells showed an incremented ability
to kill.
Induction of [Ca21]i Mobilization by Anti-P46 mAb and
p58-mediated Inhibition. In these experiments we analyzed
whether NK cell triggering via p46 involved [Ca21]i in-
creases, similar to other triggering surface molecules ex-
pressed by NK cells (6). As shown in Fig. 7 a, a sharp
[Ca21]i increase could be detected in the representative
clone KK26 (p461, p58.11, p50.31) after stimulation with
anti-p46 mAb. However, [Ca21]i increments occurred
only in the presence of a goat anti–mouse second reagent
(i.e., in the presence of efficient cross-linking of P46 mole-
cules).
Moreover, the anti-p46–induced [Ca21]i increase did
not occur upon engagement of inhibitory NKR expressed
on the same cells. For example, the p46-dependent [Ca21]i
increase in clone KK26 was completely inhibited by cross-
linking of the p58.1 inhibitory NKR (Fig. 7 b). This effect
occurs only when both anti-p46 and anti-p58.1 mAbs of
IgG1 isotype are co–cross-linked by an IgG1-specific sec-
Figure 5. The p46-mediated NK cell triggering is downregulated by
the cross-linking of HLA–class I specific inhibitory receptors. Three rep-
resentative NK cell clones expressing different HLA–class I specific inhib-
itory receptors were analyzed for cytolytic activity in a redirected killing
assay against the FcgR1 P815 target cells in the absence (h) or presence
of anti-NKR (j), anti-p46 ( ), both anti-p46 and anti-NKR ( ), or
both anti-p46 and anti-CD56 ( ) mAbs. The anti-NKR mAbs were
represented by: EB6 (anti-p58.1) in clone KK26; Z199 (anti-CD94/
NKG2A complex) in clone KK4; and Z27 (anti-p70) in clone LO1.
Figure 6. p46-mediated triggering
of cytolytic activity in fresh peripheral
blood NK cells. (a) Freshly isolated
peripheral blood NK cells were ana-
lyzed for their ability to kill the indi-
cated FcgR1 target cells in the ab-
sence of mAb (h) or presence of anti-
CD16 ( ), BAB281 (j), or anti-
CD56 mAb ( ). The effector target
ratio was 20:1 against P815 target cells
and 10:1 against K562 target cells. (b)
Freshly isolated PBL were sorted ac-
cording to the lack of expression of
p46 (s) or CD3 (m) or both p46 and
CD3 (*) and compared to unfraction-
ated cells (d) for cytolytic activity
against  51Cr-labeled K562 target cells
in the absence of added mAbs.1134 A Novel Receptor Involved in Natural Killer Cell Triggering
ond reagent. On the other hand, when the p46 and p58.1
molecules are separately cross-linked (i.e., by the use of
mAbs of different isotypes followed by two distinct iso-
type-specific second reagents) no inhibitory effect could be
detected. In control experiments the co–cross-linking me-
diated by anti-p46 and anti-CD56 mAbs of the same IgG1
isotype did not result in inhibition (not shown). In Fig. 7 c,
we analyzed for comparison the effect of cross-linking of
p50.3 molecules (an activating form of NKR belonging to
the p58/p50 family). This experiment shows that the
[Ca21]i increase induced by anti-p50.3 mAb (19) in clone
KK26 also requires cross-linking of p50.3 molecules. More-
over,  similar to p46 molecules, downregulation of the
p50.3-mediated [Ca21]i increase by an inhibitory NKR
(p58.1) occurred only when the two molecules were co–
cross-linked (Fig. 7 d).
Discussion
In this study, we identified and characterized a novel 46-kD
surface molecule. This p46 molecule is specifically ex-
pressed by human NK cells and mediates efficient NK cell
triggering leading to [Ca21]i mobilization, cytolytic activ-
ity, and cytokine production.
The precise identification of NK cells has long been
hampered by the lack of specific markers. Thus, the lack of
CD3/TCR in cells expressing CD16 and CD56 is gener-
ally considered a reliable surface phenotype for defining
NK cells (26). However, a small fraction of peripheral
blood NK cells (CD56bright) do not express CD16 (22).
Remarkably, this CD162 NK cell population is more fre-
quent in tissues (1). P46 was found to be expressed not
only by conventional CD561CD161 NK cells but also by
CD56brightCD162 cells. Typical NK cell markers including
CD56, CD16, and NKR-P1 are not unique to NK cells
but can be expressed by subsets of peripheral T cells. In ad-
dition, a variable fraction of T cells has been found to ex-
press HLA class I–specific inhibitory or activating receptors
typical of NK cells (i.e., p58, p70, p140, and CD94/
NKG2A) (27–29). Both fresh T cell populations or T cell
clones expressing these markers and/or one or more HLA
class I–specific NKR did not react with anti-p46 mAb.
Therefore, p46 appears to identify NK cells more precisely
than any of the other NK cell markers available so far.
mAb-induced ligation of p46 molecules strongly trig-
gered the NK cell-mediated cytolytic activity. This func-
tional effect was particularly evident in NK cell clones but
could also be detected in freshly isolated NK lymphocytes.
Among NK cell clones, both the CD561CD161 and the
CD561162 clones were activated by anti-p46 mAb. Anti-
p46–induced triggering was inhibited by the simultaneous
cross-linking of inhibitory NK receptors for HLA class I
molecules including p58, p70, and CD94/NKG2A. We
show that the independent cross-linking of inhibitory re-
ceptors and p46 is not sufficient for inhibiting the function
of p46 and that inhibition was achieved only when the two
molecules were co-aggregated at the NK cell surface. Thus
the cross-talk between inhibitory and activating receptors
takes place when they are co-polarized as previously sug-
gested by Blery et al. (30). Indeed these authors showed
that the FceRI-dependent degranulation of RBL-2H3 cells
transfected with the p58.2 molecules was inhibited when
the FceRI and the p58.2 receptors were co-aggregated. Al-
though there is now a better understanding on the role of
MHC molecules in NK cell functions and on the role of
the MHC-specific inhibitory receptors, limited informa-
tion exists on the molecules and the mechanisms of NK
cell triggering. A number of surface molecules is likely to
play an activating role in the process of NK cell–mediated
lysis upon interaction with ligands expressed on target cells.
Activating receptors for HLA-C molecules (p50) have re-
cently been described (21, 31). Although their role may be
physiologically relevant and they may substantially contrib-
ute to NK cell triggering in the case of HLA-C1 target
cells, it should be stressed that a major characteristic of NK
cells (including those expressing the p50 receptors) is their
ability to lyse MHC class I–negative target cells. Thus, acti-
vating receptors specific for non-MHC ligands must play a
fundamental role in the NK-mediated target cell lysis.
However, the surface molecules that are primarily responsi-
ble for the MHC-independent activation of NK cells have
not been defined. It is of note that, in most instances, mol-
ecules which mediate NK cell triggering are also expressed
by other cell types. For example, CD2 (32) and CD69 (33)
and the molecules recognized by the PP35 (34) and C1.7
(35) mAbs are expressed by variable proportions of T lym-
phocytes. Other molecules mediating strong NK cell acti-
vation, such as CD16 (15), are triggered upon interaction
with immune complexes and do not appear to play a role
in the NK cell–mediated natural cytotoxicity. Also, in ro-
dents a number of molecules involved in NK cell triggering
has been described. These include the NKR-P1 molecule,
Figure 7. Anti–p46-mediated [Ca21]i mobilization. Clone KK26
(p461, p58.11, p50.31) was analyzed for [Ca21]i mobilization after stimu-
lation with anti-p46 (a) or anti-p46 plus anti-p58.1 (b) mAb followed by
isotype-specific goat anti–mouse. (c and d) It is also shown that the [Ca21]i
mobilization induced by anti-p50.3 mAb (c) can be downregulated by the
co–cross-linking of the activating molecules (p50.3) with the inhibitory
NK receptor (p58.1) (d). All the mAbs used here were of the IgG1 iso-
type.1135 Sivori et al.
a 60-kD homodimer, able to trigger both cytotoxicity and
calcium mobilization (36), and the gp42 molecule, which is
selectively expressed on IL-2–activated NK cells (37). In
addition, the existence of an activating NK receptor spe-
cific for CD80 molecules has been suggested (38). How-
ever, this receptor is still undefined. More recently, the Ly-
49D receptor, an NK cell subset–specific homodimer of
z100 kD, has been implied in NK cell triggering (39). At
the present, it is still unclear whether Ly-49D, similar to
other members of the Ly-49 family, also recognizes MHC
molecules.
Preliminary experiments using HLA class I–negative tar-
get cell lines transfected with different HLA class I alleles
suggested that p46 does not recognize HLA class I mole-
cules. Thus, p46 may rather represent a relevant candidate
for an activating receptor involved in the recognition of
non-MHC ligands expressed by NK-susceptible target
cells. Along this line, a common view of the mechanism of
NK cell triggering in the process of natural cytotoxicity is
that multiple receptors are expressed on NK cells and may
cooperate to induce optimal cell activation (5, 40, 41). Not
necessarily all different triggering receptors simultaneously
operate since their functional engagement may depend on
the presence and/or the density of their specific ligands on
target cells. This might explain why anti-p46 mAb could
inhibit the cytolytic activity of NK clones against some (but
not all) FcgR-negative target cells. The fact that in these
cases only a partial inhibition could be detected suggests
that p46 may cooperate with other receptors to induce op-
timal NK cell triggering. Cloning of p46 molecules will al-
low us to establish possible correlations between p46 and
other functional molecules expressed by NK cells and, pos-
sibly, to identify the ligand by the use of soluble p46 mole-
cules.
Address correspondence to Dr. Alessandro Moretta, Istituto di Istologia ed Embriologia Generale, Università
di Genova, Via G.B. Marsano 10, 16132 Genova, Italy. Phone: 39-10-353-7862; FAX: 39-10-353-7576.
Received for publication 6 March 1997 and in revised form 17 July 1997.
References
1. Herberman, R.B., M.E. Nunn, and D.H. Lavrin. 1976. Nat-
ural cytotoxic reactivity of mouse lymphoid cells against syn-
geneic and allogeneic tumours. I. Distribution of reactivity
and specificity. Int. J. Cancer. 16:216–229.
2. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Im-
munol. 47:187–376.
3. Liao, N.S., M. Bix, M. Zijstra, R. Jaenisch, and D. Raulet.
1991. MHC class I deficiency: susceptibility to natural killer
(NK) cells and impaired NK activity. Science (Wash. DC).
253:199–202.
4. Karre, K. 1992. An unexpected petition for pardon. Curr.
Biol. 2:613–616.
5. Moretta, L., E. Ciccone, M.C. Mingari, R. Biassoni, and A.
Moretta. 1994. Human NK cells: origin, clonality, specificity
and receptors. Adv. Immunol. 55:341–380.
6. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni,
M.C. Mingari, and L. Moretta. 1996. Receptors for HLA-
class I molecules in human Natural Killer cells. Annu. Rev.
Immunol. 14:619–648.
7. Colonna, M., and J. Samaridis. 1995. Cloning of immuno-
globulin-superfamily members associated with HLA-C and
HLA-B recognition by human natural killer cells. Science
(Wash. DC). 268:405–408.
8. Wagtmann, N., R. Biassoni, C. Cantoni, S. Verdiani, M.S.
Malnati, M. Vitale, C. Bottino, L. Moretta, A. Moretta, and
E.O. Long. 1995. Molecular clones of the p58 NK cell re-
ceptor reveal immunoglobulin related molecules with diver-
sity in both the extra- and intracellular domains. Immunity. 2:
439–449.
9. D’Andrea, A., C. Chang, K. Franz-Bacon, T. McClanahan,
J.H. Phillips, and L.L. Lanier. 1995. Molecular cloning of
NKB1. A natural killer cell receptor for HLA-B allotypes. J.
Immunol. 155:2306–2310.
10. Moretta, A., M. Vitale, S. Sivori, C. Bottino, L. Morelli, R.
Augugliaro, M. Barbaresi, D. Pende, E. Ciccone, M. Lopez-
Botet, and L. Moretta. 1994. Human natural killer cell recep-
tors for HLA-class I molecules. Evidence that the Kp43
(CD94) molecule functions as receptor for HLA-B alleles. J.
Exp. Med. 180:545–555.
11. Sivori, S., M. Vitale, C. Bottino, E. Marcenaro, L. Sanseverino,
L., S. Parolini, L. Moretta, and A. Moretta. 1996. CD94 func-
tions as a natural killer cell inhibitory receptor for different
HLA-Class-I alleles. Identification of the inhibitory form of
CD94 by the use of novel monoclonal antibodies. Eur. J. Im-
munol. 26:2487–2492.
12. Carretero, M., C. Cantoni, T. Bellón, C. Bottino, R. Bias-
soni, A. Rodríguez, J.J. Pérez-Villar, L. Moretta, A. Moretta,
and M. López-Botet. 1997. The CD94 and NKG2-A C-type
lectins covalently assemble to form a NK cell inhibitory re-
ceptor for HLA class I molecules. Eur. J. Immunol. 27:563–567.
13. Lazetic, S., C. Chang, J.P. Houchins, L.L. Lanier, and J.H.
Phillips. 1996. Human Natural Killer cell receptors involved
in MHC class I recognition are disulphide-linked heterodimers
of CD94 and NKG2 subunits. J. Immunol. 157:4741–4745.
14. Vivier, E., M. Ackerly, N. Rochet, and P. Anderson. 1992.
Structure and function of the CD16zg complex expressed on
human natural killer cells. Int. J. Cancer. 7:11–14.
15. Azzoni, L., M. Kamoun, T.W. Salcedo, P. Kanakaraj, and B.
Perussia. 1992. Stimulation of FcgRIIIA results in phospholi-
pase C-g1 tyrosine phosphorylation and p56lck activation. J.
Exp. Med. 176:1745–1750.
16. Bezouska, K., C. Yuen, J. O’Brien, R.A. Childs, W. Chai,
A.M. Lawson, K. Drbal, A. Fiserova, M. Pospisil, and T.
Feizi. 1994. Oligosaccharide ligands for NKR.P1 protein ac-
tivate NK cells and cytotoxicity. Nature (Lond.). 372:150–
157.
17. Moretta, A., G. Tambussi, C. Bottino, G. Tripodi, A. Merli,
E. Ciccone, G. Pantaleo, and L. Moretta. 1990. A novel sur-1136 A Novel Receptor Involved in Natural Killer Cell Triggering
face antigen expressed by a subset of human CD32CD161
natural killer cells. Role in cell activation and regulation of
cytolytic function. J. Exp. Med. 171:695–714.
18. Moretta, A., G. Pantaleo, L. Moretta, M.C. Mingari, and J.C.
Cerottini. 1983. Direct demonstration of the clonogenic po-
tential of every human peripheral blood T cells. Clonal analy-
sis of HLA-DR expression and cytolytic activity. J. Exp. Med.
157:743–754.
19. Bottino, C., S. Sivori, M. Vitale, C. Cantoni, M. Falco, D.
Pende, L. Morelli, R. Augugliaro, G.P. Semenzato, R. Bias-
soni, et al. 1996. A novel surface molecule homologous to
the p58/p50 family of receptors is selectively expressed on a
subset of human Natural Killer cells and induces both trigger-
ing of cell functions and proliferation. Eur. J. Immunol. 26:
1816–1824.
20. Lanier, L.L., J.J. Ruitenberg, and J.H. Phillips. 1988. Func-
tional and biochemical analysis of CD16 antigen on natural
killer cells and granulocytes. J. Immunol. 141:3478–3485.
21. Moretta, A., S. Sivori, M. Vitale, D. Pende, L. Morelli, R.
Augugliaro, C. Bottino, and L. Moretta. 1995. Existence of
both inhibitory (p58) and activatory (p50) receptors for
HLA-C molecules in human natural killer cells. J. Exp. Med.
182:875–884.
22. Lanier, L.L., A.M. Le, C.I. Civin, M.R. Loken, and J.H.
Phillips. 1986. The relationship of CD16 (Leu-11) and Leu-
19 (NKH-1) antigen expression on human peripheral blood NK
cells and cytotoxic T lymphocytes. J. Immunol. 136:4480–4486.
23. Moretta, A., M. Vitale, C. Bottino, A.M. Orengo, L. Mo-
relli, R. Augugliaro, M. Barbaresi, E. Ciccone, and L. Mo-
retta. 1993. P58 molecules as putative receptors for MHC
class I molecules in human natural killer (NK) cells. Anti-p58
antibodies reconstitute lysis of MHC class I-protected cells in
NK clones displaying different specificities. J. Exp. Med. 178:
597–604.
24. Vitale, M., S. Sivori, D. Pende, R. Augugliaro, C. Di Do-
nato, A. Amoroso, M. Malnati, C. Bottino, L. Moretta, and
A. Moretta. 1996. Physical and functional independency of
p70 and p58 cell receptors for HLA-class I. Their role in the
definition of different groups of alloreactive NK cell clones.
Proc. Natl. Acad. Sci. USA. 93:1453–1457.
25. Litwin, V., J.E. Gumperz, P. Parham, J.H. Phillips, and L.L.
Lanier. 1994. NKB1: a Natural Killer cell receptor involved
in the recognition of polymorphic HLA-B molecules. J. Exp.
Med. 180:537–543.
26. Lanier, L.L., J. Phillips, J. Hackett, M. Tutt, and V. Kumar.
1986. Natural killer cells: definition of a cell type rather than
a function. J. Immunol. 137:2375–2380.
27. Mingari, M.C., C. Vitale, A. Cambiaggi, F. Schiavetti, G.
Melioli, S. Ferrini, and A. Poggi. 1995. Cytolytic T lympho-
cytes displaying natural killer (NK)-like activity. Expression
of NK-related functional receptors for HLA class I molecules
(p58 and CD94) and inhibitory effect on the TCR-mediated
target cell lysis or lymphokine production. Int. Immunol. 7:
697–703.
28. Mingari, M.C., M.C. Cambiaggi, C. Vitale, F. Schiavetti, R.
Bellomo, and A. Poggi. 1996. Effect of superantigens on hu-
man thymocytes: selective proliferation of Vb21 cells in re-
sponse to the toxic shock syndrome toxin-1 (TSST-1) and
their deletion upon secondary stimulation. Int. Immunol. 8:
203–209.
29. Phillips, J.H., J.E. Gumperz, P. Parham, and L.L. Lanier.
1995. Superantigen-dependent, cell-mediated cytotoxicity
inhibited by MHC class I receptor on T lymphocytes. Science
(Wash. DC). 128:403–405.
30. Blery, M., J. Delon, A. Trautmann, R. Biassoni, L. Moretta,
P. Chavrier, A. Moretta, M. Daeron, and E. Vivier. 1997.
Inhibition of ITAM-dependent cell degranulation by killer
cell MHC receptors. J. Biol. Chem. 272:8989–8996.
31. Biassoni, R., C. Cantoni, M. Falco, S. Verdiani, C. Bottino,
M. Vitale, R. Conte, A. Poggi, A. Moretta, and L. Moretta.
1996. The HLA-C–specific “activatory” or “inhibitory” nat-
ural killer cell receptors display highly homologous extracel-
lular domains but differ in their transmembrane and intracy-
toplasmic portions. J. Exp. Med. 183:645–650.
32. Bolhuis, R.L., R.C. Roozemond, and R.J. Van de Griend.
1986. Induction and blocking of cytolysis in CD21, CD32
NK and CD21, CD31 cytotoxic T lymphocytes via CD2
50 kD sheep erythrocyte receptor. J. Immunol. 136:3939–3944.
33. Moretta, A., A. Poggi, D. Pende, G. Tripodi, A.M. Orengo,
N. Pella, R. Augugliaro, C. Bottino, E. Ciccone, and L.
Moretta. 1991. CD69-mediated pathway of lymphocyte acti-
vation. Anti–CD69 mAbs trigger the cytolytic activity of dif-
ferent lymphoid effector cells with the exception of cytolytic
T lymphocytes expressing TCR-a/b. J. Exp. Med. 174:
1393–1398.
34. Moretta, A., C. Bottino, G. Tripodi, M. Vitale, D. Pende, L.
Morelli, R. Augugliaro, M. Barbaresi, E. Ciccone, R. Millo,
and L. Moretta. 1992. Novel surface molecules involved in
human NK cell activation and triggering of the lytic machin-
ery. Int. J. Cancer. 7:6–10.
35. Valiante, N.M., and G. Trinchieri. 1993. Identification of a
novel signal transduction surface molecules on human cyto-
toxic lymphocytes. J. Exp. Med. 178:1397–1406.
36. Ryan, J.C., E.C. Niemi, M.C. Nakamura, and W.E. Seaman.
1995. NKR-P1 is a target-specific receptor that activates
Natural Killer cell cytotoxicity. J. Exp. Med. 181:1911–1915.
37. Seaman, W.E., E.C. Niemi, M.R. Stark, R.D. Goldfien, A.S.
Pollock, and J.B. Imboden. 1991. Molecular cloning of gp42,
a cell-surface molecule that is selectively induced on rat natu-
ral killer cells by interleukin 2: glycolipid membrane anchor-
ing and capacity for transmembrane signaling. J. Exp. Med.
173:251–260.
38. Chambers, B.J., M. Salcedo, and H.G. Ljiunggren. 1996.
Triggering of natural killer cells by the costimulatory mole-
cule CD80 (B7.1). Immunity. 5:311–317.
39. Mason, L.H., S.K. Anderson, W.M. Yokoyama, H.R.C.
Smith, R. Winkler-Pickett, and J.R. Ortaldo. 1996. The Ly-
49D receptor activates murine natural killer cells. J. Exp.
Med. 184:2119–2128.
40. Hersey, P., and R. Bolhuis. 1987. “Nonspecific” MHC-unre-
stricted killer cells and their receptors. Immunol. Today. 8:
233–239.
41. Lanier, L.L., and J.H. Phillips. 1992. Triggering structures on
NK cells. In Cytotoxic Cells: Generation, Recognition, Ef-
fector Functions, and Methods. M. Sitkovsky and P. Hen-
kart, editors. Birkhauser Press, Boston, MA. 84–95.